Pfizer and BioNTech said that updated data from a Phase 2-3 clinical trial shows the bivalent booster performed better against the BA.4 and BA.5 omicron subvariants.
Pfizer and BioNTech said that updated data from a Phase 2-3 clinical trial shows the bivalent booster performed better against the BA.4 and BA.5 omicron subvariants.
